The HER2 ELISA Kits Market is characterized by diverse applications and growing competition among diagnostic technology providers. WiseGuyReports projects the market to increase from approximately USD 800 million in 2025 to USD 1.2 billion by 2035, expanding at a CAGR of 4.4%.

The market can be segmented according to application, end use, product type, detection method, and geography. Diagnostic applications represent an important segment because HER2 testing supports cancer diagnosis and biomarker evaluation. Research applications are also expanding as scientists investigate HER2 expression across different cancer types and therapeutic approaches.

By product type, the industry includes ready-to-use, concentrated, and multiplex kits. Detection technologies include colorimetric, fluorescent, and chemiluminescent methods. These technologies address different laboratory requirements concerning sensitivity, efficiency, and testing workflows.

Hospitals, diagnostic laboratories, and research institutions constitute the major end-user categories. Hospitals are important users because of increasing demand for cancer diagnostics, while laboratories provide specialized testing services. Research institutions contribute to technological advancement and development of new testing methodologies.

Major companies identified in the market include Bio-Rad Laboratories, Roche, Sigma-Aldrich, Abbott Laboratories, Merck KGaA, PerkinElmer, Thermo Fisher Scientific, Danaher, and Agilent Technologies.

Competition is increasingly influenced by product quality, sensitivity, innovation, regulatory compliance, distribution capabilities, and research partnerships. These factors are expected to shape future competitive strategies.